Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Treasury Shares (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Treasury Shares for 7 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 45.86% to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 45.86% increase, with the full-year FY2025 number at $6.0 million, up 45.86% from a year prior.
  • Treasury Shares was $6.0 million for Q4 2025 at Akebia Therapeutics, down from $6.2 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $7.9 million in Q2 2023 to a low of $99558.0 in Q4 2021.
  • A 4-year average of $3.6 million and a median of $3.9 million in 2023 define the central range for Treasury Shares.
  • Biggest YoY gain for Treasury Shares was 50.6% in 2025; the steepest drop was 88.96% in 2025.
  • Akebia Therapeutics' Treasury Shares stood at $99558.0 in 2021, then skyrocketed by 3254.7% to $3.3 million in 2023, then increased by 23.01% to $4.1 million in 2024, then surged by 45.86% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Treasury Shares are $6.0 million (Q4 2025), $6.2 million (Q3 2025), and $476268.0 (Q2 2025).